Search

Displaying results 4271 - 4280 of 7502 in total
  1. Drug

    Tyramine

    go.drugbank.com/drugs/DB08841
    InvestigationalNutraceutical

    Tyramine acts by inducing the release of catecholamine. … An important characteristic of this product is its impediment to cross the blood-brain barrier which restrains its side effects to only nonpsychoactive peripheral sympathomimetic effects.

  2. Drug

    Sparteine

    go.drugbank.com/drugs/DB06727
    ApprovedWithdrawn

    It is a sodium channel blocker, so it falls in the category of class 1a antiarrhythmic agents. … Sparteine is not currently FDA-approved for human use, and its salt, sparteine sulfate, is one of the products that have been withdrawn or removed from the market for reasons of safety or effectiveness

  3. Drug

    BI-K0376

    go.drugbank.com/drugs/DB05858
    Experimental

    It is under investigation by Pfizer and has gone through phase I of the clinical trails.

  4. Drug

    NLX-P101

    go.drugbank.com/drugs/DB05924
    Experimental

    NLX-P101, gene therapy is developed by Neurologix to treat Parkinson’s disease. … NLX-P101 is being evaluated as a therapeutic drug when injected into this deep brain structure that is known to function abnormally in Parkinson’s patients.

  5. Drug

    Delorazepam

    go.drugbank.com/drugs/DB01511
    IllicitInvestigational

    It is a long acting benzodiazepine which makes it superior in this sense to lorazepam which is short acting. Lorazepam is also a major active metabolite of delorazepam. … In addition to be long acting, delorazepam is relatively potent, with 1 mg of delorazepam being the equivalent of 10 mg diazepam. It has been approved for marketing in Italy.

  6. Drug

    Panobacumab

    go.drugbank.com/drugs/DB15342
    Investigational

    Panobacumab is under investigation in clinical trial NCT00851435 (Safety and Pharmacokinetics of KBPA-101 in Hospital Acquired Pneumonia Caused by O11 Pseudomonas Aeruginosa).

  7. Drug

    INNO-305

    go.drugbank.com/drugs/DB06025
    Investigational

    INNO-305 is an investigational vaccine developed by Innovive Pharmaceuticals for the treatment of patients with acute myeloid leukemia in complete remission.

  8. Drug

    Zolazepam

    go.drugbank.com/drugs/DB11555
    ExperimentalVet approved

    It is around four times the potency of diazepam but it is both water-soluble and un-ionized at physiological pH meaning that its onset is very fast.

  9. Drug

    Canertinib

    go.drugbank.com/drugs/DB05424
    Investigational

    Canertinib treatment significantly affects tumour metabolism, proliferation and hypoxia as determined by PET.

  10. Drug

    RI 624

    go.drugbank.com/drugs/DB05892
    Experimental

    RI 624 is being developed by Rinat and is currently in Phase I clinical trials.